<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312672</url>
  </required_header>
  <id_info>
    <org_study_id>MGT010</org_study_id>
    <nct_id>NCT04312672</nct_id>
  </id_info>
  <brief_title>Long Term Follow-Up Gene Therapy Study for XLRP RPGR</brief_title>
  <official_title>Long Term Follow-Up Study of Participants Following an Open Label, Multi-Centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-Associated Virus Vector (AAV2-RPGR) for Gene Therapy of Adults and Children With X-Linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The is a Long-Term Follow-up study assessing safety of patients for up to 60 months following
      AAV2 vector in participants with XLRP caused by mutations in RPGR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the long-term safety of AAV2-RPGR vector administered in the MGT009 trial</measure>
    <time_frame>60 Months</time_frame>
    <description>Safety is defined as the absence of ATIMP-related:
Reduction in visual acuity by 15 ETDRS letters or more from MGT009 baseline
Severe unresponsive inflammation
Infective endophthalmitis
Ocular malignancy
Grade III or above non-ocular SUSAR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore the longer term efficacy of AAV2-RPGR in improving visual and retinal function, quality of life and protecting against sight impairment from retinal degeneration.</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>The secondary outcomes are measures of the longer-term efficacy of the original intervention, which will be performed on an individual participant basis and will be descriptive in nature.
Efficacy will be assessed at several time points between 12 months and 5 years after the intervention:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slowing or halting of progressive deterioration in retinal structure or visual function.</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>OCT and fundus phtotography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any improvement in visual function from baseline</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Measured by visual acuity and visual mobility assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any improvement in retinal function from pre-intervention.</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Perimetry tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be measured by PRO tools</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Slowing or halting of progressive deterioration in retinal structure or visual function.
Any improvement in visual function from baseline. .EQ5D, IVI and low luminance questionnaires will be administered</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>X-Linked Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Follow up cohort</arm_group_label>
    <description>no intervention follow up study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV-RPGR</intervention_name>
    <description>Genetic</description>
    <arm_group_label>Follow up cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males receiving AAV2-RPGR in the MGT009 study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received AAV2-RPGR in the MGT009 Study

        Exclusion Criteria:

          -  Unwilling or unable to meet with the requirements of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ocular Information</last_name>
    <phone>+44203866 4320</phone>
    <email>ocularinfo@meiragtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Bainbrisge, MD</last_name>
      <email>james.bainbridge1@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

